ArticleDrug design, development and therapy2025
Exploring the Mechanism of 2'-Hydroxychalcone Improving Copper Sulfate-Induced Inflammation in Zebrafish Through Network Pharmacology.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Assessment of Cellular Apoptosis Induced by Hydroxychalcones in MCC13 Merkel Cells.International journal of molecular sciences · 2026Article
- From plant disease to protective agent: tea blister blight aqueous extract restore copper-induced oxidative and inflammatory damage in zebrafish model.Frontiers in nutrition · 2026Article
- Zebrafish as a multimodal platforms for anti-inflammatory phytomedicine discovery and translation.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: 2'-Hydroxychalcone is universally acknowledged as a Chinese medicine monomer featured by aromatic properties, exhibiting anti-inflammatory and antioxidant effects. As a consequence, the study emphasis was placed on the anti-inflammatory, anti-oxidative and exercise capacity reinforcement effects of 2'-Hydroxychalcone on Methods: Upon mating breeding, mature transgenic zebrafish and type AB zebrafish expressing red fluorescent macrophages T g (mpeg1:m Cherry) were cultured for 72 h and exposed to 12.5, 6.25, 3.14 and 0uM 2'-Hydroxychalcone, respectively, for three hours of pretreatment, which were subsequently incubated in CuSO4 at 20uM concentration for 12 h. A diverse array of test indexes was hereby utilized, encompassing the migration of red fluorescent-labeled macrophages, levels of inflammatory cytokines, zebrafish behavioral motility, and gene expression patterns correlated with oxidative stress and mitochondrial biogenesis, to assess the drugs' efficacy in alleviating inflammation. Results: 2'-Hydroxychalcone anti-inflammatory target protein was found by adopting the bioinformatics method. Its effect on zebrafish behavior ability and the change trend of oxidative stress index were explored by changing the functional state of the target, such as changing the functional activity of the target by micro-injection technology. As indicated by the results, 2'-Hydroxychalcone could hinder the migration of macrophages and the mitochondrial function of CuSO4. Apart from that, 2'-Hydroxychalcone could lessen the level of inflammatory factors and oxidative stress. In addition, 2'-Hydroxychalcone conspicuously hindered the expression of interleukin-1β and interleukin-TNF-α, and lowered the expression of COX2. An augment in the levels of the target protein TRPV1 was observed during inflammation. Discussion: The experimental findings validated the anti-inflammatory and anti-oxidant activities of 2'-Hydroxychalcone and preliminarily confirmed the effect of the target on the behavior and oxidative stress level of zebrafish.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.